BACKGROUND: Endoscopic ultrasound (EUS)-guided ethanol ablation has emerged as an efficacious and safe alternative management option for pancreatic cysts. We undertook a meta-analysis and systematic review to assess the overall safety and efficacy of EUS-guided ethanol ablation of pancreatic cysts. METHOD STUDY SELECTION CRITERIA: EUS-guided ethanol ablation of pancreatic cysts. DATA COLLECTION EXTRACTION: Articles were searched in Medline, Pubmed, and Ovid journals. STATISTICAL METHOD: Fixed and random effects models were used to calculate the pooled proportions. RESULTS: Initial search identified 1,319 reference articles, in which 120 relevant articles were selected and reviewed. Data was extracted from seven studies (n = 152) of EUS-guided ethanol ablation of pancreatic cysts, which met the inclusion criteria. With EUS-guided ethanol ablation, the pooled proportion of patients with complete cyst resolution was 56.20 % (95 % CI = 48.16 to 64.08) and partial cyst resolution was 23.72 % (95 % CI = 17.24 to 30.89). Postprocedural complications after ablation were significant for abdominal pain in 6.51 % (95 % CI = 3.12 to 11.04) and pancreatitis in 3.90 % (95 % CI = 1.39 to 7.60) of the pooled percentage of patients. Publication bias calculated using Harbord-Egger bias indicator gave a value of -1.09 (95 % CI = 10.21 to 8.03, p = 0.77). The Begg-Mazumdar indicator gave a Kendall's tau b value of 0.05 (p ≥ 0.99). CONCLUSIONS: EUS-guided ethanol ablation may be a safe alternative treatment modality for pancreatic cysts, with acceptable intraprocedural and postprocedural complications. However, due to the limited data available, prospective randomized controlled trials with a long follow up period are required in this area.
BACKGROUND: Endoscopic ultrasound (EUS)-guided ethanol ablation has emerged as an efficacious and safe alternative management option for pancreatic cysts. We undertook a meta-analysis and systematic review to assess the overall safety and efficacy of EUS-guided ethanol ablation of pancreatic cysts. METHOD STUDY SELECTION CRITERIA: EUS-guided ethanol ablation of pancreatic cysts. DATA COLLECTION EXTRACTION: Articles were searched in Medline, Pubmed, and Ovid journals. STATISTICAL METHOD: Fixed and random effects models were used to calculate the pooled proportions. RESULTS: Initial search identified 1,319 reference articles, in which 120 relevant articles were selected and reviewed. Data was extracted from seven studies (n = 152) of EUS-guided ethanol ablation of pancreatic cysts, which met the inclusion criteria. With EUS-guided ethanol ablation, the pooled proportion of patients with complete cyst resolution was 56.20 % (95 % CI = 48.16 to 64.08) and partial cyst resolution was 23.72 % (95 % CI = 17.24 to 30.89). Postprocedural complications after ablation were significant for abdominal pain in 6.51 % (95 % CI = 3.12 to 11.04) and pancreatitis in 3.90 % (95 % CI = 1.39 to 7.60) of the pooled percentage of patients. Publication bias calculated using Harbord-Egger bias indicator gave a value of -1.09 (95 % CI = 10.21 to 8.03, p = 0.77). The Begg-Mazumdar indicator gave a Kendall's tau b value of 0.05 (p ≥ 0.99). CONCLUSIONS: EUS-guided ethanol ablation may be a safe alternative treatment modality for pancreatic cysts, with acceptable intraprocedural and postprocedural complications. However, due to the limited data available, prospective randomized controlled trials with a long follow up period are required in this area.
Authors: G A Porter; P W Pisters; C Mansyur; A Bisanz; K Reyna; P Stanford; J E Lee; D B Evans Journal: Ann Surg Oncol Date: 2000-08 Impact factor: 5.344
Authors: S Ian Gan; Christopher C Thompson; Gregory Y Lauwers; Brenna C Bounds; William R Brugge Journal: Gastrointest Endosc Date: 2005-05 Impact factor: 9.427
Authors: Cristina R Ferrone; Camilo Correa-Gallego; Andrew L Warshaw; William R Brugge; David G Forcione; Sarah P Thayer; Carlos Fernández-del Castillo Journal: Arch Surg Date: 2009-05
Authors: F Monzani; F Lippi; O Goletti; P Del Guerra; N Caraccio; P V Lippolis; L Baschieri; A Pinchera Journal: J Clin Endocrinol Metab Date: 1994-03 Impact factor: 5.958
Authors: Hyoung-Chul Oh; Dong Wan Seo; Tae Yoon Lee; Ji Young Kim; Sang Soo Lee; Sung Koo Lee; Myung-Hwan Kim Journal: Gastrointest Endosc Date: 2008-02-11 Impact factor: 9.427